Maarten J G Leening

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4379690/publications.pdf

Version: 2024-02-01

79 papers	3,707 citations	185998 28 h-index	133063 59 g-index
79 all docs	79 docs citations	79 times ranked	7201 citing authors

#	Article	IF	Citations
1	Association of Cardiometabolic Multimorbidity With Mortality. JAMA - Journal of the American Medical Association, 2015, 314, 52.	3.8	624
2	Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification. Annals of Internal Medicine, 2012, 156, 438.	2.0	330
3	Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. JAMA - Journal of the American Medical Association, 2014, 311, 1416.	3.8	301
4	Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ, The, 2014, 349, g5992-g5992.	3.0	230
5	Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. European Journal of Epidemiology, 2012, 27, 173-185.	2.5	195
6	Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes and Endocrinology,the, 2016, 4, 44-51.	5.5	192
7	Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. Nature Medicine, 2019, 25, 1364-1369.	15.2	132
8	Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death. Journal of the American Heart Association, 2016, 5, .	1.6	82
9	Comparison of Atherosclerotic Calcification in Major Vessel Beds on the Risk of All-Cause and Cause-Specific Mortality. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	81
10	Declining incidence of sudden cardiac death from 1990â€“2010 in a general middle-aged and elderly population: The Rotterdam Study. Heart Rhythm, 2015, 12, 123-129.	0.3	73
11	Resting Heart Rate and the Risk of Heart Failure in Healthy Adults. Circulation: Heart Failure, 2013, 6, 403-410.	1.6	69
12	Carotid Intimaâ€Media Thickness and Arterial Stiffness and the Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study, Multiâ€Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study. Journal of the American Heart Association, 2016, 5, .	1.6	66
13	Lifetime risk and multimorbidity of non-communicable diseases and disease-free life expectancy in the general population: A population-based cohort study. PLoS Medicine, 2019, 16, e1002741.	3.9	66
14	Prevalence and determinants of healthcare avoidance during the COVID-19 pandemic: A population-based cross-sectional study. PLoS Medicine, 2021, 18, e1003854.	3.9	65
15	Coronary Calcification and the Risk of Heart Failure in the Elderly. JACC: Cardiovascular Imaging, 2012, 5, 874-880.	2.3	61
16	Development and Validation of a Dementia Risk Prediction Model in the General Population: An Analysis of Three Longitudinal Studies. American Journal of Psychiatry, 2019, 176, 543-551.	4.0	61
17	Development and Validation of a Coronary Risk Prediction Model for Older U.S. and European Persons in the Cardiovascular Health Study and the Rotterdam Study. Annals of Internal Medicine, 2012, 157, 389.	2.0	58
18	Disability and not osteoarthritis predicts cardiovascular disease: a prospective population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 752-756.	0.5	57

#	Article	IF	Citations
19	Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. PLoS ONE, 2015, 10, e0130072.	1.1	57
20	Use of Coumarin Anticoagulants and Cerebral Microbleeds in the General Population. Stroke, 2014, 45, 3436-3439.	1.0	55
21	Lifetime risk of common neurological diseases in the elderly population. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 148-156.	0.9	50
22	Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective. Statistics in Medicine, 2014, 33, 3415-3418.	0.8	47
23	Subclinical cardiac dysfunction increases the risk of stroke and dementia. Neurology, 2015, 84, 833-840.	1.5	42
24	Unrecognised myocardial infarction and long-term risk of heart failure in the elderly: the Rotterdam Study. Heart, 2010, 96, 1458-1462.	1.2	38
25	Epicardial Fat Volume and the Risk of AtrialÂFibrillation in the General Population Free of Cardiovascular Disease. JACC: Cardiovascular Imaging, 2017, 10, 1405-1407.	2.3	38
26	Healthy Volunteer Effect and Cardiovascular Risk. Epidemiology, 2014, 25, 470-471.	1.2	36
27	Statin use is associated with carotid plaque composition: The Rotterdam Study. International Journal of Cardiology, 2018, 260, 213-218.	0.8	35
28	Clopidogrel Use Is Associated With an Increased Prevalence of Cerebral Microbleeds in a Strokeâ€Free Population: The Rotterdam Study. Journal of the American Heart Association, 2013, 2, e000359.	1.6	31
29	Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. European Respiratory Journal, 2017, 49, 1602168.	3.1	29
30	The association of innate and adaptive immunity, subclinical atherosclerosis, and cardiovascular disease in the Rotterdam Study: A prospective cohort study. PLoS Medicine, 2020, 17, e1003115.	3.9	29
31	Unrecognized myocardial infarction and risk of atrial fibrillation: The Rotterdam Study. International Journal of Cardiology, 2013, 168, 1453-1457.	0.8	28
32	Lifetime Perspectives on Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2016, 315, 1449.	3.8	28
33	Leveraging the coronary calcium scan beyond the coronary calcium score. European Radiology, 2018, 28, 3082-3087.	2.3	26
34	Use of antidepressants and the risk of myocardial infarction in middle-aged and older adults: a matched case-control study. European Journal of Clinical Pharmacology, 2016, 72, 211-218.	0.8	24
35	Comparison of Prognosis in Unrecognized Versus Recognized Myocardial Infarction in Men Versus Women >55 Years of Age (from the Rotterdam Study). American Journal of Cardiology, 2014, 113, 1-6.	0.7	23
36	Associations of Heart Failure with Sleep Quality: The Rotterdam Study. Journal of Clinical Sleep Medicine, 2015, 11, 117-121.	1.4	23

#	Article	IF	Citations
37	Sex-specific distributions and determinants of thoracic aortic diameters in the elderly. Heart, 2020, 106, 133-139.	1.2	22
38	Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives. Biometrical Journal, 2015, 57, 556-570.	0.6	21
39	Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease. JAMA Cardiology, 2016, 1, 708.	3.0	20
40	Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. Journal of the American Heart Association, 2018, 7, e007514.	1.6	20
41	Utilisation of cardiac pacemakers over aÂ20-year period: Results from aÂnationwide pacemaker registry. Netherlands Heart Journal, 2017, 25, 47-55.	0.3	19
42	Lifetime risk to progress from pre-diabetes to type 2 diabetes among women and men: comparison between American Diabetes Association and World Health Organization diagnostic criteria. BMJ Open Diabetes Research and Care, 2020, 8, e001529.	1.2	19
43	Comparing a marginal structural model with a Cox proportional hazard model to estimate the effect of time-dependent drug use in observational studies: statin use for primary prevention of cardiovascular disease as an example from the Rotterdam Study. European Journal of Epidemiology, 2014, 29, 841-850.	2.5	17
44	Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?. European Heart Journal, 2017, 38, ehw287.	1.0	17
45	Performance of Framingham cardiovascular disease (CVD) predictions in the Rotterdam Study taking into account competing risks and disentangling CVD into coronary heart disease (CHD) and stroke. International Journal of Cardiology, 2014, 171, 413-418.	0.8	16
46	Assessing Prolongation of the Heart Rate Corrected QT Interval in Users of Tricyclic Antidepressants. Journal of Clinical Psychopharmacology, 2015, 35, 260-265.	0.7	15
47	The Revised Framingham Stroke Risk Profile in a Primary Prevention Population. Circulation, 2017, 135, 2207-2209.	1.6	15
48	Nâ€terminal proâ€Bâ€type natriuretic peptide and the risk of stroke and transient ischaemic attack: the Rotterdam Study. European Journal of Neurology, 2015, 22, 695-701.	1.7	14
49	Trends in service time of pacemakers in the Netherlands: aÂlong-term nationwide follow-up study. Netherlands Heart Journal, 2017, 25, 581-591.	0.3	11
50	Net reclassification improvement: a link between statistics and clinical practice. European Journal of Epidemiology, 2013, 28, 21-23.	2.5	9
51	Fibrosis and Mortality in Patients With Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2013, 309, 2547.	3.8	9
52	Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments. PLoS Medicine, 2018, 15, e1002539.	3.9	9
53	Changes in the Diagnosis of Stroke and Cardiovascular Conditions in Primary Care During the First 2 COVID-19 Waves in the Netherlands. Neurology, 2022, 98, e564-e572.	1.5	9
54	Subclinical Abnormalities in Echocardiographic Parameters and Risk of Sudden Cardiac Death in a General Population: The Rotterdam Study. Journal of Cardiac Failure, 2016, 22, 17-23.	0.7	8

#	Article	IF	Citations
55	Sex-specific added value of cardiac biomarkers for 10-year cardiovascular risk prediction. European Journal of Preventive Cardiology, 2022, 29, 1559-1567.	0.8	7
56	The long-term risk of recognized and unrecognized myocardial infarction for depression in older men. Psychological Medicine, 2016, 46, 1951-1960.	2.7	6
57	Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study. Respiratory Medicine, 2017, 132, 50-55.	1.3	6
58	Who Benefits From Taking a Statin, and When?. Circulation, 2020, 142, 838-840.	1.6	5
59	Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007183.	0.9	5
60	Markers for Prediction of Cardiovascular Disease Risk. JAMA - Journal of the American Medical Association, 2012, 308, 2561.	3.8	4
61	Trends in replacement of pacemaker leads in the Netherlands: A longâ€term nationwide followâ€up study. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 820-827.	0.5	4
62	Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study. European Journal of Epidemiology, 2018, 33, 403-413.	2.5	3
63	The accuracy of mean corpuscular volume guided anaemia classification in primary care. Family Practice, 2021, 38, 735-739.	0.8	3
64	Arterial calcification at different sites and prediction of atherosclerotic cardiovascular disease among women and men. Atherosclerosis, 2021, 337, 27-34.	0.4	3
65	Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: Results from the Rotterdam Study. Atherosclerosis, 2020, 299, 64-66.	0.4	2
66	Plasma amyloid-Î²40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study. Atherosclerosis, 2022, 348, 44-50.	0.4	2
67	Are osteoarthritis patients at high risk of cardiovascular disease? Results from a large prospective population-based cohort study. European Heart Journal, 2013, 34, P919-P919.	1.0	1
68	Screening for heart failure in the elderly and the competition of coâ€morbidity. What if we could prevent heart failure from reaching the finish line first?. European Journal of Heart Failure, 2013, 15, 477-477.	2.9	1
69	Absolute vs Additive Net Reclassification Index. JAMA - Journal of the American Medical Association, 2018, 319, 616.	3.8	1
70	Recurrent Late Bioresorbable Scaffold Thrombosis as a Presenting Symptom of Underlying Cancer. Journal of the American College of Cardiology, 2018, 71, 259-260.	1.2	1
71	Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. European Journal of Epidemiology, 2021, 36, 1103-1109.	2.5	1
72	New onset atrial fibrillation and long-term risk of heart failure in the general population: the Rotterdam study. European Heart Journal, 2013, 34, P4094-P4094.	1.0	0

#	Article	IF	Citations
73	Coronary calcium scores: From histology to preventive cardiology. International Journal of Cardiology, 2017, 229, 34.	0.8	0
74	P6213Differences in recommendations and associated level of evidence for statins in primary prevention of CVD according to the ACC/AHA 2013, CCS 2016, ESC 2016, and USPSTF 2016 clinical practice guidelines. European Heart Journal, 2017, 38, .	1.0	0
75	Title is missing!. , 2020, 17, e1003115.		0
76	Title is missing!. , 2020, 17, e1003115.		0
77	Title is missing!. , 2020, 17, e1003115.		0
78	Title is missing!. , 2020, 17, e1003115.		0
79	Title is missing!. , 2020, 17, e1003115.		0